RESCUE: Discontinuation of GLP-1
Terminated · NCT07190794
Conditions: Obesity
At a glance
- Research payments reported, 2025
- $5,000
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 18
About the trial
- Sponsor
- Boston Scientific Corporation
- Tested
- OverStitch™ or OverStitch NXT™ (device), Lifestyle Modification (behavioral)
- Dates
- Started 2025-12-17; completion 2026-05-26
- Results posted
- Not yet
This study is designed to compare weight loss outcomes and safety of ESG versus lifestyle modification in patients with obesity who discontinued GLP-1 therapy due to intolerance or suboptimal weight loss.
From ClinicalTrials.gov, last updated 2026-07-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Boston Scientific Corporation reported $5,000 in research payments for this study in 2025 (1 payments).
Products named: Clinical Trial Product
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Bariendo Medical Group PA $5,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.